GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » Graham Number

vTv Therapeutics (vTv Therapeutics) Graham Number : $N/A (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-06-09), the stock price of vTv Therapeutics is $17.10. vTv Therapeutics's graham number for the quarter that ended in Mar. 2024 was $N/A. Therefore, vTv Therapeutics's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for vTv Therapeutics's Graham Number or its related term are showing as below:

VTVT's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 2.03
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


vTv Therapeutics Graham Number Historical Data

The historical data trend for vTv Therapeutics's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

vTv Therapeutics Graham Number Chart

vTv Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

vTv Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of vTv Therapeutics's Graham Number

For the Biotechnology subindustry, vTv Therapeutics's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Price-to-Graham-Number falls into.



vTv Therapeutics Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

vTv Therapeutics's Graham Number for the fiscal year that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*-11.837*-9.71)
=N/A

vTv Therapeutics's Graham Number for the quarter that ended in Mar. 2024 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*8.548*-8.48)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


vTv Therapeutics  (NAS:VTVT) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

vTv Therapeutics's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Mar. 2024 )
=17.10/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


vTv Therapeutics Graham Number Related Terms

Thank you for viewing the detailed overview of vTv Therapeutics's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


vTv Therapeutics (vTv Therapeutics) Business Description

Traded in Other Exchanges
Address
3980 Premier Drive, Suite 310, High Point, NC, USA, 27265
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. The company lead program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes.
Executives
Steven L. Tuch officer: Chief Financial Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry director C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Paul J Sekhri director, officer: President and CEO C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Fahed Al-marzooqi director AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris director C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov director WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner director 4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S. 10 percent owner OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd. director, 10 percent owner OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown officer: Chief Accounting Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson director, officer: Acting Chief Executive Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman 10 percent owner 35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad director, officer: President and CEO C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265

vTv Therapeutics (vTv Therapeutics) Headlines

From GuruFocus